The World Anti-Microbial Resistance Congress

The World Anti-Microbial Resistance Congress

Source:

Healio Interview

Disclosures: Outterson is employed by CARB-X, a global nonprofit organization funded by BARDA.
November 11, 2021
1 min watch
Save

VIDEO: Sustainable funding of antibiotic development

Source:

Healio Interview

Disclosures: Outterson is employed by CARB-X, a global nonprofit organization funded by BARDA.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

WASHINGTON – Kevin Outterson, JD, LLM, delivered a keynote fireside chat during the World Anti-Microbial Resistance Congress that discussed novel pull incentives to develop antibiotics in the United States.

“One of the things I think people don’t know enough about is how important antibiotics are to everything else in the health care system,” said Outterson, a professor of law at Boston University and executive director of CARB-X. “But we’re not paying for them in a sustainable fashion.”

CARB-X, which is part of Boston University, is a global public-private partnership dedicated to accelerating antibacterial research. It is funded by the Biomedical Advanced Research and Development Authority (BARDA) and other groups.

Outterson recently published a research article that discusses some of the pull incentives being used to pay for antibiotics.